|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Center For Virus Research, Westmead Millennium
Institute, Sydney, Australia; National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda, MD; and
Mater Medical Research Institute, Brisbane, Australia.
Dendritic cells (DCs) are important targets for human
immunodeficiency virus (HIV) because of their roles during transmission and also maintenance of immune competence. Furthermore, DCs are a key
cell in the development of HIV vaccines. In both these settings the
mechanism of binding of the HIV envelope protein gp120 to DCs is of
importance. Recently a single C-type lectin receptor (CLR), DC-SIGN,
has been reported to be the predominant receptor on monocyte-derived
DCs (MDDCs) rather than CD4. In this study a novel biotinylated gp120
assay was used to determine whether CLR or CD4 were predominant
receptors on MDDCs and ex vivo blood DCs. CLR bound more than 80% of
gp120 on MDDCs, with residual binding attributable to CD4, reconfirming
that CLRs were the major receptors for gp120 on MDDCs. However, in
contrast to recent reports, gp120 binding to at least 3 CLRs was
observed: DC-SIGN, mannose receptor, and unidentified trypsin resistant
CLR(s). In marked contrast, freshly isolated and cultured
CD11c+ve and CD11c Dendritic cells (DCs) play a major role in human
immunodeficiency virus (HIV) pathogenesis. Peripheral or surveillance
mucosal DCs are one of the first cell types infected and are
distributed in the vaginal, ectocervical, and anal
mucosa,1,2 allowing contact with HIV during mucosal
exposure. Thus, after vaginal inoculation with simian immunodeficiency
virus in macaques, DCs are the predominant cell type
infected.3 Furthermore, the ability of DCs to cluster with
and stimulate T cells may also play a key role in establishing
infection. DCs from skin, mucosa, and blood of humans and macaques can
participate in highly productive HIV and simian immunodeficiency virus
infection in DC-T-cell cocultures and illustrates the importance of
this natural DC-T-cell synergy.4-7
Key aspects of HIV binding to DC via gp120 are ill-defined,
particularly to the different types of DCs. CD11c+ve and
CD11c This study aimed to define the contributions of CD4 and CLRs in binding
gp120, to address and identify the capacity of other CLRs including
DC-SIGN during monocyte differentiation to mature MDDCs and, more
importantly, to compare such populations with ex vivo blood DCs.
Understanding the mechanisms of gp120 binding to different DC
populations would help define the early events of HIV transmission via
DCs in blood or mucosal tissue and improve intervention strategies.
Definition of the mechanisms of HIV/gp120 binding and processing by DCs
will also assist future HIV vaccine strategies and immunotherapy.
MDDC generation and culture
Isolation and culture of blood DCs
HIV gp120 binding and inhibition studies Purified HIV gp120 from the BaL isolate (courtesy of Ray Sweet, SmithKline Beecham, King of Prussia, PA) was biotinylated with EZ-Link NHS-LC-Biotin as per the manufacturer (Pierce, Rockford, IL). Biotinylation of gp120 did not affect the ability of the molecule to bind to CD4 and was confirmed in an sCD4 capture enzyme-linked immunosorbent assay with detection via streptavidin horseradish peroxidase (data not shown). In addition, nonbiotinylated gp120 material from the isolates BaL and 92MW959, using detection with purified and biotinylated human polyclonal antibodies from HIV-seropositive patients (Cellular Products, Buffalo, NY), produced equivalent results to biotinylated gp120 from respective isolates. In particular, the saturating concentrations of gp120 and the relative binding of gp120 by CD4 and CLR on MDDCs were the same by both methods. However, biotinylated gp120 binding assay was routinely used because it reduced one additional antibody staining step, reduced the variability of antibody binding, and allowed for flexibility when working with blood DCs, which are labeled with multiple antibodies for detection of multiple DC subsets.For binding and inhibition studies, cells were preincubated for 40 minutes in binding media (RPMI 1640 without sodium bicarbonate [Gibco] with 1% bovine serum albumin and 10 mM HEPES [Calbiochem, San Diego, CA] pH 7.4) as above at 4°C with stated concentrations of inhibitors, followed by incubation with b-gp120 (2-fold the predetermined concentration for cellular saturation). Levels of inhibitors, with the exception of mAbs, were initially determined using a broad range of concentrations to assess the maximal level of gp120 blocking. In the cases of mAb, concentrations were routinely 5-fold that of cellular saturation. Cells were then washed twice, and measurement of bound b-gp120 was carried out by incubation of 1 × 106 cells (2 × 105 cells/200 µL) with 5 µg/mL streptavidin Oregon Green 488 (Molecular Probes, Eugene, OR) or avidin FITC (Becton Dickinson) and detected by flow cytometry. Flow cytometric analysis For surface staining, cells were treated as previously described.29 In gp120 binding studies, cells were preincubated with b-gp120 at various concentrations for 40 minutes at 4°C in binding media. Antibodies used were CD14-phycoerythrin (PE), immunoglobulin G1 (IgG1)-PE, IgG1-FITC, CD3-FITC, IgG1, goat antimouse FITC (all from Becton Dickinson), CD83, CD86, CD1a-FITC, MR (clones 19 and 3.29), and HLA-DR-PE/P5 (all from PharMingen, San Diego, CA, except anti-MR 3.29, which is from Immunotech, Marseille, France). The CD4 mAbs used were Leu3a (Becton Dickinson), OKT4 (American Type Culture Collection, Manassas, VA), and Q4120 (a generous gift from Quentin Sattentau). The mAbs to DC-SIGN (AZN-D1 and AZN-D2) and associated experiments were a part of the 7th Leukocyte Differentiation DC Antigen Workshop (kindly donated by Yvette van Kooyk). Detection of b-gp120 and biotinylated polyclonal sera to HIV (Cellular Products) was via strepdavidin Oregon Green 488 or avidin FITC.DC-SIGN reverse transcriptase-polymerase chain reaction Cells were prepared as above apart from monocytes that were positively selected over a magnetic-activated cell separation column according to the manufacturer (Miltenyi Biotech). The CD11c+ve and CD11c ve blood DCs selected
Vantage fluorescent cell sorting. Total RNA was prepared from
10 000 cells using TRIzol (Gibco) as per the manufacturer. The cDNA
was synthesized from DNaseI-treated RNA with oligo-dT primers and
Superscript II (Gibco). From 40 µL of RNase H-treated cDNA, 1 µL
was polymerase chain reaction (PCR)-amplified with Taq polymerase
(Qiagen, Germany) using either the GAPDH primers, 5'-ATGGGGAAGGTGAAGGTCGGA-3' and 5'-AGGGGCCATCCACAGTCTTCTG-3', to ensure
equivalent amounts of cDNA in each cell type or using the first-round
DC-SIGN primers, 5'AGAGTGGGGTGACATGAGTG-3' and 5'-GAAGTTCTGCTACGCAGGAG-3', which yielded a fragment approximately 1.2 kilobases in size. A seminested round of PCR was performed for DC-SIGN
using the former 5' primer and 5'-AGCTCCTGGTAGATCTCCTGC-3'. Electrophoresed products were transferred from a 1% agarose gel to
Hybond N+ and probed with digoxigenin-labeled internal
oligonucleotide 5'-CCAGAGAAATCTAAGCTGCAGG-3' as per the manufacturer
(Roche Biochemicals, Basel, Switzerland).
HIV gp120 internalization and tracking To examine gp120 internalization, cells were labeled with b-gp120 as described above, washed, and subsequently incubated at 37°C. For short-term incubations (< 2 hours) cells were incubated in a 37°C water, and for longer incubations (> 2 hours) cells were replated and cultured at 37°C in a 5% CO2 incubator. Aliquots were removed at the times outlined in "Results" and terminated by incubation in 0.25% (wt/vol) paraformaldehyde in phosphate-buffered saline at 4°C for 30 minutes. For internal staining, cells were permeabilized with 0.2% (vol/vol) Tween 20, 1% (vol/vol) fetal calf serum in phosphate-buffered saline for 15 minutes at 37°C. Detection of external or internal gp120 was via streptavidin Oregon Green 488 as described above.
HIV gp120 binding to CLR and/or CD4 on immature MDDCs Because of its potent inhibition of CLRs15 and lack of interference with gp120-CD4 binding, mannan was chosen as an inhibitory ligand to determine the proportion of gp120 bound to CLRs in MDDCs.15 In MDDCs, mannan inhibited gp120 by up to 84% (Figure 1A). Higher levels of mannan were also used (up to 25 mg/mL), but further gp120 blocking was not observed (data not shown). Nonbiotinylated Chinese hamster ovary cell-expressed gp120 (detected via anti-HIV polyclonal antibodies) from the primary R5 isolate MW959 was also inhibited with mannan by up to 80% (data not shown). The other CLR inhibitor, -methyl-mannopyranoside, and the
calcium chelator, ethyleneglycotetraacetic acid (EGTA), inhibited gp120
binding by 82% and 77%, respectively (Figure
2). The residual gp120 binding was
initially attributed to CD4. Therefore, the gp120-blocking CD4 mAbs
Leu3a and Q4120, with the nonblocking mAb OKT4 as a negative control,
were used to determine CD4 binding. However, neither Leu3a nor Q4120
could block gp120 binding at concentrations up to 25 µg/mL (Figure
1B). In view of this CLR-gp120 binding predominance, incubation with
CD4 mAbs after prior blocking of CLR binding was examined. To achieve
this, MDDCs were preincubated with 5 mg/mL mannan and then with
increasing amounts of the Leu3a. In the absence of CLR binding,
anti-Leu3a was successful at inhibiting the residual 10% to 20% gp120
binding to less than 1% of gp120 binding (Figure 1B).
Inhibition of mAb binding to specific CLRs by gp120 Candidate CLRs on MDDCs and other DCs for gp120 binding were DC-SIGN and MR.14,30 Therefore, mAb DC-SIGN (AZN-D2)14,16 and MR (clone 19)31 were used because they have been shown previously to block ligand binding. Preincubation of MDDCs with gp120 inhibited DC-SIGN (AZN-D2), MR (clone 19), and CD4 (Leu3a) mAbs in a dose-dependent manner (Figure 3A). As gp120 approached cellular saturation, binding of the mAbs to all 3 receptors approached zero. The gp120 concentrations that inhibited mAb binding by 50% (Ki) mAb were, for DC-SIGN (AZN-D2), 1 nM; MR (clone 19), 4 nM; and CD4 (Leu3a), 14 nM. The approximate dissociation constant (Kd) for BaL gp120 from the gp120 saturation curve is 6 nM for 1 × 106/mL MDDCs.
The role of individual CLRs in binding gp120 In reciprocal experiments, the effects of prior incubation with MR (clones 19 and 3.29) and DC-SIGN (AZN-D1 and AZN-D2) blocking mAbs on gp120 binding14,16,31,32 were examined to determine relative importance of DC-SIGN and MR in gp120 binding. However, anti-MR (clones 19 and 3.29) and anti-DC-SIGN (AZN-D1 and AZN-D2) mAbs could not inhibit gp120 binding (at levels up to 5 µg/mL). The antibody bound was confirmed in each assay by goat antimouse PE, and it was confirmed that gp120 and the blocking antibodies were each bound to saturating levels on the entire MDDC population (data not shown). However, in the same assay mannan successfully reduced gp120 binding below 20% and combined mannan and Leu3a to below 1%. Because gp120 was used in excess in the above experiments, further inhibitory studies with 5-fold saturating concentrations of mAb (5 µg/mL) were carried out over a range of gp120 concentrations (20 ng/mL to 5 µg/mL) to observe the effects of MR and DC-SIGN mAbs (Figure 3B). However, no significant inhibition of gp120 binding by MR and/or DC-SIGN antibodies was observed at any concentration.HIV gp120 binding to trypsin-insensitive CLRs To address the possibility that MDDCs express several CLRs capable of binding gp120, cells were trypsinized to denude them of both the CD4-gp120 binding site and the carbohydrate recognition domains (CRDs) of either DC-SIGN and/or the MR. As expected, the CD4 Leu3a epitope was cleaved. The CRD for DC-SIGN was also trypsin-sensitive, whereas the MR clone 19 epitope was not (Figure 4Biii). When trypsinized MDDCs were exposed to gp120, they retained the ability to bind gp120 at a reduced level (Figure 4Di). If trypsinized cells were preexposed to mannan or EGTA, they lost their ability to bind to gp120, indicating binding was carbohydrate- and calcium-dependent, characteristic of a trypsin-resistant CLR but clearly not DC-SIGN (Figure 4Dii, iii, respectively). To address whether this CLR might be MR, the anti-MR mAb clones 19 and 3.29 were used to block the trypsin-insensitive gp120 binding. However, MR mAb clones 19 and 3.29 could not significantly reduce trypsin-insensitive gp120 binding (Figure 4Div). To ensure that the mAbs can block gp120 binding, parallel studies were carried out with a transfected cell line expressing macrophage mannose receptor (MMR).33 The MMR mAbs could inhibit gp120 binding to 50% regardless of whether these cells were trypsinized (data not shown); ie, the mAbs were partial inhibitors of gp120 binding to MMR on the transfected cell line but had no effect on MDDCs regardless of whether they were trypsinized.
HIV gp120 binding during differentiation of monocytes to MDDCs The switch from gp120 binding to CD4 on monocytes to CLRs on MDDCs was examined during in vitro differentiation over 6 days. By day 2, CLR binding was predominant (Figure 5B) and correlated with a rise in MR expression and CD4 down-regulation (Figure 5A). Over day 2 to day 6 of differentiation, there was a continuous increase in binding of gp120 to CLR with a corresponding decrease in CD4 binding. Over the same period, there was a continuous increase in DC-SIGN, CD4, and MR expression. The peak expression of all 3 receptors at day 6 coincided with the peak in gp120 binding (Figure 5A). Mature MDDCs were generated by stimulation with TNF- for 2 days. After
maturation, MR, DC-SIGN, and CD4 were all down-regulated, but this was
more marked with MR (Figure 5A). In mature MDDCs, the pattern of gp120
binding to CLRs and CD4 converged, with intermediate levels of binding
to both (Figures 5B and 7B).
HIV gp120 binding on ex vivo blood DCs Because MDDCs are derived in vitro, it was important to determine the gp120 binding receptors on ex vivo blood DCs. Blood DCs were separated, incubated with gp120, and triple-stained for b-gp120, CD11c, and HLA-DR, which allowed identification of 2 blood DC populations based on the presence or absence of CD11c expression. The CD11cve population expressed much higher levels of CD4
(Figure 6A) and bound greater amounts of
gp120 than the CD11c+ve population (Figure
7A). CD4 was down-regulated on both blood DC subsets after overnight culture (data not shown) and was reflected by the reduced capacity to bind gp120 (Figure 7A). The importance of
CLRs and CD4 for gp120 binding was determined by blocking experiments with mannan and anti-CD4 (Leu3a) mAbs (Figure 7B). The pattern of
binding was similar on both blood DC subsets both fresh and after
overnight culturewith a predominance of gp120 binding to CD4 rather
than CLRs. The lack of CLR binding was supported by the lack of MR
(data not shown) and DC-SIGN surface expression (Figure 6A).
Seminested reverse transcriptase (RT)-PCR for DC-SIGN confirmed
lack of messenger RNA transcripts in both blood DC subsets. However,
transcripts were seen in PBMC and CD14+ve monocyte
populations (Figure 6B).
HIV gp120 internalization Internalization was rapid, with less than 50% of surface gp120 present after 5 minutes. After 1 hour no external gp120 could be observed on MDDCs (Figure 8). MDDCs were reexamined for surface gp120 over 2, 6, 18, and 24 hours. There was no reappearance of external gp120 over the period of 1 to 24 hours. The kinetics of gp120 internalization mediated by CD4 and CLRs was also investigated. First, the CLR pathway was blocked by mannan, and gp120 bound to CD4 was examined for internalization. Conversely, the role of CLRs in internalization was also examined by blocking CD4 with Leu3a and gp120 subsequently tracked. Both CD4 and CLR pathways exhibited rapid internalization with no external gp120 evident after 60 minutes. The CD4-mediated internalization pathway showed a single rapid phase, but CLR internalization was biphasic. The first phase rapidly internalized most of the gp120 within the first 15 minutes, and the second phase internalized the residual gp120 over the 15- to 60-minute period. Rapid external loss of gp120 correlated with rapid appearance of internalized gp120 as observed in permeabilized MDDCs (Figure 8).
MDDCs were used in the current studies as a model for immature tissue DCs such as skin LCs and mucosal DCs. They are a convenient model for in vitro studies but also may have relevance in vivo: Monocytes are observed to develop into MDDCs at sites of inflammation as a second recruitment of antigen-presenting cells.34 Nethertheless, they show marked phenotypic difference to other blood and tissue DCs.35 Therefore, we defined the receptors for binding gp120 on MDDCs in vitro and then compared them with ex vivo blood DCs. In MDDCs, 2 groups of receptors capable of binding gp120 were defined.
MDDCs bound gp120 predominantly via CLRs: the mannose saccharides,
mannan and mannopyranoside, and also calcium depletion were capable of
markedly inhibiting gp120 binding. Monocytes only bound gp120 via CD4
and did not express MR or DC-SIGN. Conversion to the predominant CLR
binding pattern seen in MDDCs occurred on monocytes after 2 days of
culture in interleukin-4/GM-CSF and peaked at day 6. During MDDC
differentiation, the kinetics of DC-SIGN, MR, and CD4 expression and
gp120 binding via CLRs were discordant, which supports a more complex
gp120 binding pattern than previously described. TNF- Both CD11c+ve and CD11c The 2 CLRs, DC-SIGN and the MR, have been previously observed to bind gp120,14,15,30 and both are expressed on MDDCs. HIV gp120 bound to the surface of MDDCs and inhibited anti-CD4, anti-MR, and anti-DC-SIGN mAb binding, supporting gp120 binding to the above 3 receptors. DC-SIGN mAb was most readily inhibited at low gp120 concentrations, consistent with high affinity for gp120.15 However, neither CD4, DC-SIGN, nor MR mAb inhibited gp120 binding to MDDCs. Trypsin treatment of MDDCs completely cleaved both the CD4 (Leu3a) and DC-SIGN (AZN-D2) mAb epitopes but only partially inhibited gp120 binding to MDDCs. Both MR mAb clones 19 and 3.29 still bound to trypsinized MDDCs, probably to CRDs 4 or 5, which are protease-insensitive.33 Residual gp120 binding, in trypsinized MDDCs, was blocked by mannan and EGTA but not by either MR mAbs. These results suggest gp120 could bind to other CLRs and/or other CRDs of MR (not recognized by the mAbs). However, the latter seems unlikely because both mAbs block binding of mannose ligands to MR31,32 and, more specifically, partially block gp120 in a trypsinized MMR cell line (data not shown). If several CLRs, including DC-SIGN and MR, can bind gp120, blocking one CLR with mAbs may not significantly reduce gp120 binding. This notion is further supported by the inability of either CD4 or CLR mAbs alone to inhibit binding. In addition, the binding of gp120 to CD4 differed in the presence or absence (mannan block) of CLRs. This might reflect the much higher binding affinity of the CLRs (MMR and DC-SIGN, Kd < 4 nM) compared with the CD4 affinity for BaL gp120 (Kd = 30 nM). Experiments on gp120 internalization independently confirmed that gp120 bound predominantly via CLRs. The rapid internalization of gp120 in COS-7-DC-SIGN transfectants observed by Curtis et al15 and in HeLa transfectants (A. J. Watson, written communication, August 2000), together with internalization of the MR,36 supports our observation of a rapid CLR-mediated phase of gp120 internalization. The biphasic nature of this CLR-based internalization could reflect multiple CLRs capable of binding and internalizing gp120. Electron microscopic studies by Blauvelt et al,8 Dezutter-Dambuyant and Schmitt,37 and Hladik et al7 showed internalization of virions into vacuoles and is consistent with current observations of gp120 internalization. In electron microscopy studies by Dezutter-Dambuyant and Schmitt,37 HIV gp120 internalization was correlated with whole virions, because both were observed in clathrin-coated pits of epidermal LCs. Similarly stable HeLa clone 11 (DC-SIGN) transfectants also internalized HIV into vacuoles, suggesting that CLR binding results in endocytosis (A. J. Watson, written communication, August 2000). In our recent work, mannan was also shown to markedly inhibit accumulation of full-length HIV proviral DNA transcripts within MDDCs, showing a close correlation between gp120 internalization and HIV infection (unpublished observations, 2001). In the current study there was no reappearance of gp120 on the surface of MDDCs, suggesting there was degradation after internalization. There are many reports of the ability of gp120 to bind to various cell types independently of CD4. Macrophages,30 trypsinized LCs,13,38 MDDCs,16 and cells within the placenta15 are examples. Only the studies of Curtis et al15 and Larkin et al30 identified the specific receptors as CLRs. Geijtenbeek et al14,16 recently reported that placental CLR clone 11 (DC-SIGN) previously described by Curtis et al15 was expressed on MDDCs. While the observations described here support CLRs as predominant receptors for gp120 binding to MDDCs, CLR binding of gp120 was not restricted to one receptor as reported previously14 but instead to multiple CLRs, including DC-SIGN and MR. A further CLR related to DC-SIGN, named DC-SIGNR, has recently been indentified on MDDCs,21 and the potential expression and binding by numerous other CLRs on MDDCs17-20 further supports our current hypothesis that multiple CLRs can bind gp120. Although CLRs bound most gp120 in MDDCs, CD4 is the predominant receptor in blood DCs. This observation expands previously described phenotypic differences between MDDCs and blood DCs.35 Thus, the fate of internalized gp120 or of HIV is highly likely to be determined by initial binding to CLRs (MDDCs) or CD4 and then the appropriate chemokine receptors (blood DCs). Transfer of HIV from blood DCs to T cells as shown by Cameron et al4 must involve initial binding by CD4. In contrast, Blauvelt et al8 observed that in vitro-derived DCs have the capacity to capture and transfer HIV independently of the CD4/chemokine receptor infection pathway. The current work and recent work by Geijtenbeek et al14 suggest that this previously unknown capture pathway is by CLRs. However, both MDDCs and blood DCs capture and transfer HIV to CD4 T lymphocytes effectively in coculture assays. In light of the current observations, it is obvious that blood DCs could not capture and transfer HIV via both pathways. Further viral binding mechanisms independent of CD4 and CLR may also be present. For instance, HIV can acquire T cell-specific molecules during budding,39,40 and DCs may be able to bind virions via the same mechanism they use in clustering to T cells. Another DC in vivo, the follicular DC, predominantly binds HIV virions via the adhesion molecules CD54 (ICAM-1) and CD11a (LFA-1).41 Macropinocytosis must also be considered as another mechanism of gp120/viral uptake by DCs. In view of the discordant findings for gp120 binding between MDDCs and blood DCs, future work must focus on which CLRs are expressed in vivo on LCs and mucosal DCs and whether CLRs or CD4 are the major receptors for gp120 in these cells. LCs do not express DC-SIGN16 and expression of the MR is controversial,24,42 but they do express a mannose-fucose binding receptor(s)42 and can bind gp120 independently of CD4.13 Therefore, other CLRs and/or CD4/CCR5 could be even more important than DC-SIGN in studies of DC-mediated HIV mucosal transmission. The study of the relevant receptors in appropriate surveillance DCs is essential to understanding both mucosal HIV transmission and systemic or mucosal gp120 antigenic processing pathways. These results are relevant to the design of effective antivirals: Care must be taken to ensure that all routes of HIV-DC binding are blocked, because DCs may bind and transfer HIV to responding CD4 T cells via several of their cell surface receptors.
We thank Ray Sweet for his generous gift of BaL gp120, Yvette van Kooyk for the supply of both antibodies AZN-D1 and AZN-D2 to DC-SIGN, Belinda Herring for her help and assistance, Parramatta Red Cross Blood Bank for its continued support, and Nancy Haigwood and Andrew Watson for helpful discussions on the placental clone 11.
Submitted April 3, 2001; accepted June 14, 2001.
Supported by grants from the Westmead Millennium Foundation, Australian National Center in HIV Virology Research, and the Mater Trust.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anthony L. Cunningham, Westmead Millennium Institute, PO Box 412, Darcy Road, Westmead, NSW 2145, Australia; e-mail: tony_cunningham{at}wmi.usyd.edu.au.
1. Edwards JN, Morris HB. Langerhans' cells and lymphocyte subsets in the female genital tract. Br J Obstet Gynaecol. 1985;92:974-982[Medline] [Order article via Infotrieve]. 2. Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest. 1992;67:628-634[Medline] [Order article via Infotrieve].
3.
Hu J, Gardner MB, Miller CJ.
Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.
J Virol.
2000;74:6087-6095 4. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 1992;257:383-387. 5. Pope M, Betjes MG, Romani N, et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell. 1994;78:389-398[CrossRef][Medline] [Order article via Infotrieve]. 6. Pope M, Elmore D, Ho D, Marx P. Dendrite cell-T cell mixtures, isolated from the skin and mucosae of macaques, support the replication of SIV. AIDS Res Hum Retroviruses. 1997;13:819-827[Medline] [Order article via Infotrieve].
7.
Hladik F, Lentz G, Akridge RE, et al.
Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract.
J Virol.
1999;73:5833-5842 8. Blauvelt A, Asada H, Saville MW, et al. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. J Clin Invest. 1997;100:2043-2053[Medline] [Order article via Infotrieve]. 9. Patterson S, Robinson SP, English NR, Knight SC. Subpopulations of peripheral blood dendritic cells show differential susceptibility to infection with a lymphotropic strain of HIV-1. Immunol Lett. 1999;66:111-116[CrossRef][Medline] [Order article via Infotrieve].
10.
Rubbert A, Combadiere C, Ostrowski M, et al.
Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry.
J Immunol.
1998;160:3933-3941
11.
Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM.
Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells.
J Virol.
1998;72:2733-2737 12. Zaitseva M, Blauvelt A, Lee S, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med. 1997;3:1369-1375[CrossRef][Medline] [Order article via Infotrieve]. 13. Schmitt D, Dezutter-Dambuyant C, Hanau D, et al. In vitro binding and internalization of HIV envelope glycoproteins by human epidermal Langerhans cells does not require the CD4-gp120-binding site. Res Virol. 1990;141:209-215[CrossRef][Medline] [Order article via Infotrieve]. 14. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587-597[CrossRef][Medline] [Order article via Infotrieve].
15.
Curtis BM, Scharnowske S, Watson AJ.
Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.
Proc Natl Acad Sci U S A.
1992;89:8356-8360 16. Geijtenbeek TB, Torensma R, van Vliet SJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell. 2000;100:575-585[CrossRef][Medline] [Order article via Infotrieve].
17.
Ariizumi K, Shen GL, Shikano S, et al.
Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms.
J Biol Chem.
2000;275:11957-11963
18.
Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL.
Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells.
Proc Natl Acad Sci U S A.
1999;96:9792-9796
19.
Bates EE, Fournier N, Garcia E, et al.
APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.
J Immunol.
1999;163:1973-1983 20. Colonna M, Samaridis J, Angman L. Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol. 2000;30:697-704[CrossRef][Medline] [Order article via Infotrieve].
21.
Soilleux EJ, Barten R, Trowsdale J.
DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13.
J Immunol.
2000;165:2937-2942 22. Stahl PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol. 1998;10:50-55[CrossRef][Medline] [Order article via Infotrieve]. 23. Kato M, Neil TK, Clark GJ, Morris CM, Sorg RV, Hart DNJ. cDNA cloning of human DEC-205, a putative antigen-uptake receptor on dendritic cells. Immunogenetics. 1998;47:442-450[CrossRef][Medline] [Order article via Infotrieve].
24.
Kato M, Neil TK, Fearnley DB, McLellan AD, Vuckovic S, Hart DN.
Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells.
Int Immunol.
2000;12:1511-1519 25. Mason RR, Weiner RS. Application of the Beckman JE6-B Elutriator System in the isolation of human monocyte subpopulations. Scand J Haematol. 1985;34:5-8[Medline] [Order article via Infotrieve].
26.
Kazazi F, Mathijs JM, Chang J, et al.
Recombinant interleukin 4 stimulates human immunodeficiency virus production by infected monocytes and macrophages.
J Gen Virol.
1992;73:941-949
27.
Romani N, Gruner S, Brang D, et al.
Proliferating dendritic cell progenitors in human blood.
J Exp Med.
1994;180:83-93
28.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J Exp Med.
1994;179:1109-1118
29.
Fear WR, Kesson AM, Naif H, Lynch GW, Cunningham AL.
Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages.
J Virol.
1998;72:1334-1344 30. Larkin M, Childs RA, Matthews TJ, et al. Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition. AIDS. 1989;3:793-798[Medline] [Order article via Infotrieve].
31.
Dong X, Storkus WJ, Salter RD.
Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells.
J Immunol.
1999;163:5427-5434
32.
Sallusto F, Cella M, Danieli C, Lanzavecchia A.
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
J Exp Med.
1995;182:389-400
33.
Taylor ME, Drickamer K.
Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor.
J Biol Chem.
1993;268:399-404 34. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 1999;11:753-761[CrossRef][Medline] [Order article via Infotrieve].
35.
Hart DN.
Dendritic cells: unique leukocyte populations which control the primary immune response.
Blood.
1997;90:3245-3287 36. Tan MC, Mommaas AM, Drijfhout JW, et al. Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells. Adv Exp Med Biol. 1997;417:171-174[Medline] [Order article via Infotrieve]. 37. Dezutter-Dambuyant C, Schmitt D. Epidermal Langerhans cells and HIV-1 infection. Immunol Lett. 1993;39:33-37[CrossRef][Medline] [Order article via Infotrieve]. 38. Dezutter-Dambuyant C, Schmitt DA, Dusserre N, et al. Trypsin-resistant gp120 receptors are upregulated on short-term cultured human epidermal Langerhans cells. Res Virol. 1991;142:129-138[CrossRef][Medline] [Order article via Infotrieve]. 39. Liao Z, Roos JW, Hildreth JE. Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses. 2000;16:355-366[CrossRef][Medline] [Order article via Infotrieve].
40.
Frank I, Kacani L, Stoiber H, et al.
Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious.
J Virol.
1999;73:3449-3454
41.
Fujiwara M, Tsunoda R, Shigeta S, Yokota T, Baba M.
Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction.
J Virol.
1999;73:3603-3607 42. Condaminet B, Peguet-Navarro J, Stahl PD, Dalbiez-Gauthier C, Schmitt D, Berthier-Vergnes O. Human epidermal Langerhans cells express the mannose-fucose binding receptor. Eur J Immunol. 1998;28:3541-3551[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  N. P. Y. Chung, S. K. J. Breun, A. Bashirova, J. G. Baumann, T. D. Martin, J. M. Karamchandani, J. W. Rausch, S. F. J. Le Grice, L. Wu, M. Carrington, et al. HIV-1 Transmission by Dendritic Cell-specific ICAM-3-grabbing Nonintegrin (DC-SIGN) Is Regulated by Determinants in the Carbohydrate Recognition Domain That Are Absent in Liver/Lymph Node-SIGN (L-SIGN) J. Biol. Chem., January 15, 2010; 285(3): 2100 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jain, S. L. Manuel, Z. K. Khan, J. Ahuja, K. Quann, and B. Wigdahl DC-SIGN Mediates Cell-Free Infection and Transmission of Human T-Cell Lymphotropic Virus Type 1 by Dendritic Cells J. Virol., November 1, 2009; 83(21): 10908 - 10921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Harman, M. Kraus, C. R. Bye, K. Byth, S. G. Turville, O. Tang, S. K. Mercier, N. Nasr, J. L. Stern, B. Slobedman, et al. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase Blood, July 2, 2009; 114(1): 85 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lai, O. K. Bernhard, S. G. Turville, A. N. Harman, J. Wilkinson, and A. L. Cunningham Oligomerization of the Macrophage Mannose Receptor Enhances gp120-mediated Binding of HIV-1 J. Biol. Chem., April 24, 2009; 284(17): 11027 - 11038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Hatch, J. Archer, and S. Gummuluru Glycosphingolipid Composition of Human Immunodeficiency Virus Type 1 (HIV-1) Particles Is a Crucial Determinant for Dendritic Cell-Mediated HIV-1 trans-Infection J. Virol., April 15, 2009; 83(8): 3496 - 3506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lambert, C. Gilbert, M. Richard, A. D. Beaulieu, and M. J. Tremblay The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways Blood, August 15, 2008; 112(4): 1299 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cannon, Y. Yi, H. Ni, E. Stoddard, D. A. Scales, D. I. Van Ryk, I. Chaiken, D. Malamud, and D. Weissman HIV Envelope Binding by Macrophage-Expressed gp340 Promotes HIV-1 Infection J. Immunol., August 1, 2008; 181(3): 2065 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Gaiha, T. Dong, N. Palaniyar, D. A. Mitchell, K. B. M. Reid, and H. W. Clark Surfactant Protein A Binds to HIV and Inhibits Direct Infection of CD4+ Cells, but Enhances Dendritic Cell-Mediated Viral Transfer J. Immunol., July 1, 2008; 181(1): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Frank, H. Stossel, A. Gettie, S. G. Turville, J. W. Bess Jr., J. D. Lifson, I. Sivin, N. Romani, and M. Robbiani A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic Cells J. Virol., June 1, 2008; 82(11): 5329 - 5339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de Witte, M. Bobardt, U. Chatterji, G. Degeest, G. David, T. B. H. Geijtenbeek, and P. Gallay Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1 PNAS, December 4, 2007; 104(49): 19464 - 19469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Angel, A. Lala, C.-J. J. Chen, S. G. Edgar, L. L. Ostrovsky, and P. R. Dunbar CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts Int. Immunol., November 1, 2007; 19(11): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.-P. Hong, S. Nguyen, S. Young, S. V. Su, and B. Lee Identification of the Optimal DC-SIGN Binding Site on Human Immunodeficiency Virus Type 1 gp120 J. Virol., August 1, 2007; 81(15): 8325 - 8336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gilbert, R. Cantin, C. Barat, and M. J. Tremblay Human Immunodeficiency Virus Type 1 Replication in Dendritic Cell-T-Cell Cocultures Is Increased upon Incorporation of Host LFA-1 due to Higher Levels of Virus Production in Immature Dendritic Cells J. Virol., July 15, 2007; 81(14): 7672 - 7682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Fahrbach, S. M. Barry, S. Ayehunie, S. Lamore, M. Klausner, and T. J. Hope Activated CD34-Derived Langerhans Cells Mediate Transinfection with Human Immunodeficiency Virus J. Virol., July 1, 2007; 81(13): 6858 - 6868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Wang, A. M. Janas, W. J. Olson, V. N. KewalRamani, and L. Wu CD4 Coexpression Regulates DC-SIGN-Mediated Transmission of Human Immunodeficiency Virus Type 1 J. Virol., March 1, 2007; 81(5): 2497 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. U. Cameron, A. J. Handley, D. C. Baylis, A. E. Solomon, N. Bernard, D. F. J. Purcell, and S. R. Lewin Preferential Infection of Dendritic Cells during Human Immunodeficiency Virus Type 1 Infection of Blood Leukocytes J. Virol., March 1, 2007; 81(5): 2297 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Smith, L. Ganesh, K. Leung, J. Jongstra-Bilen, J. Jongstra, and G. J. Nabel Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells J. Exp. Med., February 19, 2007; 204(2): 421 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Harman, J. Wilkinson, C. R. Bye, L. Bosnjak, J. L. Stern, M. Nicholle, J. Lai, and A. L. Cunningham HIV Induces Maturation of Monocyte-Derived Dendritic Cells and Langerhans Cells J. Immunol., November 15, 2006; 177(10): 7103 - 7113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caminschi, A. J Corbett, C. Zahra, M. Lahoud, K. M Lucas, M. Sofi, D. Vremec, T. Gramberg, S. Pohlmann, J. Curtis, et al. Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN Int. Immunol., May 1, 2006; 18(5): 741 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Turville, K. Vermeire, J. Balzarini, and D. Schols Sugar-Binding Proteins Potently Inhibit Dendritic Cell Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Dendritic-Cell-Directed HIV-1 Transfer J. Virol., November 1, 2005; 79(21): 13519 - 13527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Granelli-Piperno, A. Pritsker, M. Pack, I. Shimeliovich, J.-F. Arrighi, C. G. Park, C. Trumpfheller, V. Piguet, T. M. Moran, and R. M. Steinman Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages in the Normal Human Lymph Node and Is Not Required for Dendritic Cell Stimulation of the Mixed Leukocyte Reaction J. Immunol., October 1, 2005; 175(7): 4265 - 4273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pashov, S. MacLeod, R. Saha, M. Perry, T. C. VanCott, and T. Kieber-Emmons Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12 Glycobiology, October 1, 2005; 15(10): 994 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dominguez-Soto, A. Puig-Kroger, M. A. Vega, and A. L. Corbi PU.1 Regulates the Tissue-specific Expression of Dendritic Cell-specific Intercellular Adhesion Molecule (ICAM)-3-grabbing Nonintegrin J. Biol. Chem., September 30, 2005; 280(39): 33123 - 33131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Su, T. Bakker, J. Harris, C. Tsang, G. D. Brown, M. R. Wormald, S. Gordon, R. A. Dwek, P. M. Rudd, and L. Martinez-Pomares Glycosylation Influences the Lectin Activities of the Macrophage Mannose Receptor J. Biol. Chem., September 23, 2005; 280(38): 32811 - 32820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Yamada, M. Montoya, C. G. Schuettler, T. P. Hickling, A. W. Tarr, A. Vitelli, J. Dubuisson, A. H. Patel, J. K. Ball, and P. Borrow Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets J. Gen. Virol., September 1, 2005; 86(9): 2507 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pashov, G. Canziani, B. Monzavi-Karbassi, S. V. Kaveri, S. MacLeod, R. Saha, M. Perry, T. C. VanCott, and T. Kieber-Emmons Antigenic Properties of Peptide Mimotopes of HIV-1-associated Carbohydrate Antigens J. Biol. Chem., August 12, 2005; 280(32): 28959 - 28965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Gagliardi, R. Teloni, F. Giannoni, M. Pardini, V. Sargentini, L. Brunori, L. Fattorini, and R. Nisini Mycobacterium bovis Bacillus Calmette-Guerin infects DC-SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production J. Leukoc. Biol., July 1, 2005; 78(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nobile, C. Petit, A. Moris, K. Skrabal, J.-P. Abastado, F. Mammano, and O. Schwartz Covert Human Immunodeficiency Virus Replication in Dendritic Cells and in DC-SIGN-Expressing Cells Promotes Long-Term Transmission to Lymphocytes J. Virol., May 1, 2005; 79(9): 5386 - 5399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Snyder, J. Ford, P. Torabi-Parizi, J. A. Arthos, P. Schuck, M. Colonna, and P. D. Sun Characterization of DC-SIGN/R Interaction with Human Immunodeficiency Virus Type 1 gp120 and ICAM Molecules Favors the Receptor's Role as an Antigen-Capturing Rather than an Adhesion Receptor J. Virol., April 15, 2005; 79(8): 4589 - 4598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Groot, T. B. H. Geijtenbeek, R. W. Sanders, C. E. Baldwin, M. Sanchez-Hernandez, R. Floris, Y. van Kooyk, E. C. de Jong, and B. Berkhout Lactoferrin Prevents Dendritic Cell-Mediated Human Immunodeficiency Virus Type 1 Transmission by Blocking the DC-SIGN--gp120 Interaction J. Virol., March 1, 2005; 79(5): 3009 - 3015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ganesh, K. Leung, K. Lore, R. Levin, A. Panet, O. Schwartz, R. A. Koup, and G. J. Nabel Infection of Specific Dendritic Cells by CCR5-Tropic Human Immunodeficiency Virus Type 1 Promotes Cell-Mediated Transmission of Virus Resistant to Broadly Neutralizing Antibodies J. Virol., November 1, 2004; 78(21): 11980 - 11987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Lederman, R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak Jr., J. D. Lifson, J. R. Salkowitz, B. Rodriguez, et al. Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 Science, October 15, 2004; 306(5695): 485 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Stebbing, B. Gazzard, and D. C. Douek Where Does HIV Live? N. Engl. J. Med., April 29, 2004; 350(18): 1872 - 1880. [Full Text] [PDF]
|
|
|
|
|
|
Q. Hu, I. Frank, V. Williams, J. J. Santos, P. Watts, G. E. Griffin, J. P. Moore, M. Pope, and R. J. Shattock Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue J. Exp. Med., April 19, 2004; 199(8): 1065 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Turville, J. J. Santos, I. Frank, P. U. Cameron, J. Wilkinson, M. Miranda-Saksena, J. Dable, H. Stossel, N. Romani, M. Piatak Jr, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells Blood, March 15, 2004; 103(6): 2170 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.-Y. Ploquin, O. M. Diop, N. Sol-Foulon, L. Mortara, A. Faye, M. A. Soares, E. Nerrienet, R. Le Grand, Y. Van Kooyk, A. Amara, et al. DC-SIGN from African Green Monkeys Is Expressed in Lymph Nodes and Mediates Infection in trans of Simian Immunodeficiency Virus SIVagm J. Virol., January 15, 2004; 78(2): 798 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gummuluru, M. Rogel, L. Stamatatos, and M. Emerman Binding of Human Immunodeficiency Virus Type 1 to Immature Dendritic Cells Can Occur Independently of DC-SIGN and Mannose Binding C-Type Lectin Receptors via a Cholesterol-Dependent Pathway J. Virol., December 1, 2003; 77(23): 12865 - 12874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Turville, J. Wilkinson, P. Cameron, J. Dable, and A. L. Cunningham The role of dendritic cell C-type lectin receptors in HIV pathogenesis J. Leukoc. Biol., November 1, 2003; 74(5): 710 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Teleshova, I. Frank, and M. Pope Immunodeficiency virus exploitation of dendritic cells in the early steps of infection J. Leukoc. Biol., November 1, 2003; 74(5): 683 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawamura, F. O. Gulden, M. Sugaya, D. T. McNamara, D. L. Borris, M. M. Lederman, J. M. Orenstein, P. A. Zimmerman, and A. Blauvelt R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms PNAS, July 8, 2003; 100(14): 8401 - 8406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nobile, A. Moris, F. Porrot, N. Sol-Foulon, and O. Schwartz Inhibition of Human Immunodeficiency Virus Type 1 Env-Mediated Fusion by DC-SIGN J. Virol., May 1, 2003; 77(9): 5313 - 5323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, G. Simmons, S. Pohlmann, F. Baribaud, H. Ni, G. J. Leslie, B. S. Haggarty, P. Bates, D. Weissman, J. A. Hoxie, et al. Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR J. Virol., January 15, 2003; 77(2): 1337 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Bashirova, L. Wu, J. Cheng, T. D. Martin, M. P. Martin, R. E. Benveniste, J. D. Lifson, V. N. KewalRamani, A. Hughes, and M. Carrington Novel Member of the CD209 (DC-SIGN) Gene Family in Primates J. Virol., January 1, 2003; 77(1): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.-P. Hong, K. B. Flummerfelt, A. de Parseval, K. Gurney, J. H. Elder, and B. Lee Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding J. Virol., December 15, 2002; 76(24): 12855 - 12865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. A. MacDonald, D. J. Munster, G. J. Clark, A. Dzionek, J. Schmitz, and D. N. J. Hart Characterization of human blood dendritic cell subsets Blood, December 15, 2002; 100(13): 4512 - 4520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gummuluru, V. N. KewalRamani, and M. Emerman Dendritic Cell-Mediated Viral Transfer to T Cells Is Required for Human Immunodeficiency Virus Type 1 Persistence in the Face of Rapid Cell Turnover J. Virol., November 1, 2002; 76(21): 10692 - 10701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Osugi, S. Vuckovic, and D. N. J. Hart Myeloid blood CD11c+ dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes Blood, September 26, 2002; 100(8): 2858 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Engering, S. J. van Vliet, T. B. H. Geijtenbeek, and Y. van Kooyk Subset of DC-SIGN+ dendritic cells in human blood transmits HIV-1 to T lymphocytes Blood, August 13, 2002; 100(5): 1780 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Frank, M. Piatak Jr., H. Stoessel, N. Romani, D. Bonnyay, J.D. Lifson, and M. Pope Infectious and Whole Inactivated Simian Immunodeficiency Viruses Interact Similarly with Primate Dendritic Cells (DCs): Differential Intracellular Fate of Virions in Mature and Immature DCs J. Virol., March 15, 2002; 76(6): 2936 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wu, A. A. Bashirova, T. D. Martin, L. Villamide, E. Mehlhop, A. O. Chertov, D. Unutmaz, M. Pope, M. Carrington, and V. N. KewalRamani Rhesus macaque dendritic cells efficiently transmit primate lentiviruses independently of DC-SIGN PNAS, February 5, 2002; 99(3): 1568 - 1573. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
mean
negative control fluorescence intensity)/mean positive control
fluorescence intensity] × 100. Positive control cells were treated
with b-gp120 in the absence of inhibitors. Negative controls consisted
of cells with identical inhibitors but no b-gp120.
